Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724042 | SCV000228491 | pathogenic | not provided | 2014-06-05 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV000724042 | SCV000927782 | pathogenic | not provided | 2018-07-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000176777 | SCV001199787 | pathogenic | Autosomal recessive polycystic kidney disease | 2023-08-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PKHD1 protein function. ClinVar contains an entry for this variant (Variation ID: 196052). This missense change has been observed in individual(s) with polycystic kidney disease (PMID: 16133180, 27225849). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs773136605, gnomAD 0.01%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 952 of the PKHD1 protein (p.Gly952Arg). |
Centre for Mendelian Genomics, |
RCV001198369 | SCV001369281 | likely pathogenic | Polycystic kidney disease 4 | 2019-12-11 | criteria provided, single submitter | clinical testing | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM1,PM2,PP3. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000176777 | SCV001737689 | pathogenic | Autosomal recessive polycystic kidney disease | 2021-05-21 | criteria provided, single submitter | clinical testing | Variant summary: PKHD1 c.2854G>A (p.Gly952Arg) results in a non-conservative amino acid change located in the IPT domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 250594 control chromosomes. c.2854G>A has been reported in the literature in multiple individuals affected with Polycystic Kidney And Hepatic Disease (Losekoot_2005, Melchionda_2016, Yao_2021). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Gene |
RCV000724042 | SCV002525272 | pathogenic | not provided | 2022-06-03 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 16133180, 27225849, 33845788) |
Baylor Genetics | RCV001198369 | SCV004202213 | pathogenic | Polycystic kidney disease 4 | 2024-01-09 | criteria provided, single submitter | clinical testing | |
Division of Human Genetics, |
RCV000176777 | SCV000536850 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2016-09-05 | no assertion criteria provided | research | |
Laboratory of Gastroenterology and Hepatology, |
RCV001844815 | SCV001876987 | likely pathogenic | Autosomal dominant polycystic liver disease | 2021-09-01 | no assertion criteria provided | research | |
Natera, |
RCV000176777 | SCV002081012 | pathogenic | Autosomal recessive polycystic kidney disease | 2020-12-21 | no assertion criteria provided | clinical testing |